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The majority of patients with dyspepsia have no identiﬁable cause of their disease, leading to a diagnosis of functional dyspepsia
(FD). While a number of diﬀerent factors aﬀect gut activity, components of the nervous and endocrine systems are essential for
normal gut function. Communication between the brain and gut occurs via direct neural connections or endocrine signaling
events. Ghrelin, a peptide produced by the stomach, aﬀects gastric motility/emptying and secretion, suggesting it may play a
pathophysiological role in FD. It is also possible that the functional abnormalities in FD may aﬀect ghrelin production in the
stomach. Plasma ghrelin levels are reported to be altered in FD, correlating with FD symptom score. Furthermore, some patients
with FD suﬀer from anorexia with body-weight loss. As ghrelin increases gastric emptying and promotes feeding, ghrelin therapy
may be a new approach to the treatment of FD.
1.Introduction
Dyspepsia is associated with a variety of organic and
functional disorders. The organic causes of dyspeptic symp-
toms include peptic ulcers, cholelithiasis, reﬂux disease, and
malignancy. In patients initially presenting with dyspepsia,
approximately 33% to 50% have an underlying organic
disease [1]. Routine clinical evaluation and procedures do
not reveal the cause of symptoms in the majority of patients
with dyspepsia. If symptoms persist for more than three
months with symptom onset of at least six months prior to
thediagnosis, aﬀectedpatientsarediagnosed withfunctional
dyspepsia (FD).
Despite an absence of organic disease in patients with
FD, abnormalities in gastric emptying, dysregulation of
gastroduodenal motility, and visceral hypersensitivity are
often associated with FD. As ghrelin aﬀects gastric motil-
ity/emptying [2–7] and secretion [8, 9], this peptide may
play a pathophysiological role in FD. It is also possible that
thefunctionalabnormalitiesinFDmayaﬀecttheproduction
of ghrelin by the stomach. Indeed, plasma ghrelin levels are
reported to be altered in FD [10, 11], frequently correlating
with FD symptom score [11, 12]. Some patients with FD also
suﬀer from anorexia with signiﬁcant weight loss, frequently
leading to diagnosis of eating disorders. As yet, no treatment
guidelines for patients with FD or eating disorders have
been established. Given its role triggering eating behaviors,
ghrelinmightbeanappropriatetreatmentforFD,potentially
improving food intake by inﬂuencing gastric emptying and
motility. In this article, we discuss FD and the potential role
of ghrelin in this disease.
2. FunctionalDyspepsia
Functional dyspepsia (FD), a functional gastroduodenal
disorder(FGDD)[13,14]andoneofthefunctionalgastroin-
testinal disorders (FGIDs) [15], was previously known as
nonulcerdyspepsia(NUD),essentialdyspepsia,oridiopathic
dyspepsia [16, 17]. The original Rome I criteria, which
established the classiﬁcation and diagnosis of FD in 1994
[18], have since been updated twice as Rome II in 2000 [19]
and Rome III in 2006 [15].
T h eR o m eI I( Table 1)[ 19] deﬁnes FD as persistent
or recurrent pain or discomfort centered in the upper
abdomen. Discomfort refers to a subjective, negative feeling2 International Journal of Peptides
Table 1: Diagnostic criteria and classiﬁcation of FD in Rome II.
Diagnostic criteria
At least 12 weeks, which need not be consecutive, in the preceding 12 months of
(1) Persistent or recurrent symptoms (pain or discomfort centered in the upper abdomen)
(2) No evidence of organic disease (including at upper endoscopy) that is likely to explain the symptoms
(3) No evidence that dyspepsia is exclusively relieved by defecation or associated with the onset of a change in stool frequency or stool
form (i.e., not irritable bowel).
Classiﬁcation
(B1a) Ulcer-like dyspepsia
Pain centered in the upper abdomen is the predominant (most bothersome) symptom.
(B1b) Dysmotility-like dyspepsia
An unpleasant or troublesome nonpainful sensation (discomfort) centered in the upper abdomen is the predominant symptom; this
sensation may be characterized by or associated with upper abdominal fullness, early satiety, bloating, or nausea.
(B1c) Unspeciﬁed (nonspeciﬁc) dyspepsia
Symptomatic patients whose symptoms do not fulﬁll the criteria for ulcer-like or dysmotility-like dyspepsia.
Table 2: Dyspeptic symptoms deﬁned by Rome III. This table is
adopted by permission from Elsevier Limited [13, 15].
Symptom Deﬁnition
Postprandial
fullness
An unpleasant sensation akin to the prolonged
persistence of food in the stomach
Early satiation
A feeling that the stomach is overﬁlled soon after
starting to eat. This feeling is out of proportion to
the size of the meal and results in the patient
being unable to ﬁnish the meal
Epigastric pain
Pain located between the umbilicus and sternum
in the midline of the torso. The pain is a
subjective and unpleasant feeling, but diﬃcult to
describe. Some patients may describe feelings of
tissue damage or chest pain
Epigastric
burning
Pain located in the epigastrium that has a burning
quality, but does not radiate to the chest
characterized by or associated with non-painful symptoms
such as upper abdominal fullness, early satiety, bloating,
or nausea. For a diagnosis, symptoms must have persisted
or recurred for at least 12 weeks over a 12-month period.
A dyspepsia subgroup classiﬁcation was also proposed
for research purposes, based on the predominant (most
bothersome) symptom, (a) ulcer-like dyspepsia features pain
(from mild to severe) as the predominant symptom, while
(b) dysmotility-like dyspepsia exhibits discomfort (not pain)
as the predominant symptom.
The Rome III system radically reformulated the classiﬁ-
cation of FD (Table 2)[ 14]. The description of symptoms
centered in the upper abdominal area was reﬁned by
the Committee to pain in the precise epigastric region,
while other key symptoms (early satiety and fullness) must
be meal-related. According to Rome III, discomfort was
abandoned as a key concept, replaced by post-prandial
fullness and early satiety. The Rome III criteria moved away
from subcategorization using the predominant symptom
(dysmotility-like and ulcer-like dyspepsia of Rome II),
Table 3: Rome III criteria for functional gastroduodenal disorders.
This table is adopted by permission from Elsevier Limited [13].
B Functional gastroduodenal disorders
B1 Functional dyspepsia (for application in clinical
practice but not otherwise useful)
B1a Postprandial distress syndrome
B1b Epigastric pain syndrome
B2 Belching disorders
B2a Aerophagia
B2b Unspeciﬁed excessive belching
B3 Nausea and vomiting disorders
B3a Chronic idiopathic nausea
B3b Functional vomiting
B3c Cyclic vomiting syndrome
B4 Rumination syndrome in adults
although similar entities, (a) postprandial distress syndrome
and (b) epigastric pain syndrome, are subsumed under the
FD section (Table 3). The Committee recognized that there
are no one symptoms present in the majority of patients
previously labeled with a diagnosis of FD. The time course
for diagnosis was made less restrictive for all functional
disorders;diagnosiswasacceptableforsymptomsoriginating
six, not 12, months prior to diagnosis when currently active
(i.e., meet criteria) for at least three months [13]. For
research purposes, the term FD was abandoned in favor of
a new classiﬁcation system described in Table 3.
Although the etiology of FD remains unclear, a number
of factors may play a role in the development of symptoms
[1]( Table 4). Visceral hypersensitivity is thought to be crit-
ical in causing FD by enhancing perception and processing
of gastrointestinal neural inputs [20]. In a study of exper-
imentally induced gut distention, the majority of patients
with FD developed greater discomfort than matched healthy
controls. As increased gut sensitivity may aﬀect gut motility,
acid secretion, and gastric distension, hypersensitivity mayInternational Journal of Peptides 3
Table 4: Postulated mechanisms leading to the development of
dyspeptic symptoms in patients with functional dyspepsia. This
table is adopted by permission from Elsevier Limited [1].
Visceral hypersensitivity
(a) Increased perception of distention
(b) Impaired or altered perception of acid
(c) Visceral hypersensitivity secondary to chronic inﬂammation
Motility disorders
(a) Postprandial antral hypomotility
(b) Reduced relaxation of the gastric fundus
(c) Decreased or impaired gastric emptying
(d) Changes of the gastric electric rhythm
(e) Gastro-esophageal reﬂux
(f) Duodeno-gastric reﬂux
Changes in acid secretion
Hyperacidity
Helicobacter pylori infection
Stress
Psychological disorders and abnormalities
Genetic predisposition
underlie many of the symptoms of FD. Patients with FD
oftenhaveconcomitantGImotilitydisordersandpsychiatric
illnesses. Whether these disorders are an epiphenomenon or
related to the underlying disease remains unclear. Symptom
development and exacerbation of FD are often linked to
stressful life events, causing the patient to seek medical help
atthattime.Thus,patientsseekingcareforFDsymptomsare
morelikelytohaveactivelifestressorsthanthosewhoremain
undiagnosed, leading to bias in the sample population.
External stressors may also aﬀect intestinal function, which
in connection with visceral hypersensitivity, may lead to
increased symptom perception.
3. Relationship of Ghrelin to the GI Tractand
FeedingBehaviors
Neural and hormonal communication between the gut and
the brain modulate appetite, feeding, and digestion [21, 22].
In the integrated gut-brain-energy axis, gastrointestinal (GI)
motility, gastric acid secretion, digestion, and defecation
are coordinated with appetite, satiation, and metabolism.
Both organic and functional GI disorders are associated
with alterations of the physiologic factors regulating the gut-
brain-energy axis.
Multiple hormones are secreted by the gut and adipose
tissues during feeding, digestion, and fasting, each of which
can profoundly aﬀect the GI tract [22]. A subset of these
hormones directly aﬀects secretory function along the GI
tract (e.g., gastrin stimulates acid secretion by parietal cells);
major sites of hormone action also include enteric and vagal
neurons, the area postrema (AP) within the medulla, and
the hypothalamic arcuate nucleus (HAN). The AP and the
median eminence, which has a close relationship with the
HAN, have greatly reduced or absent blood-brain barriers.
Impulses from the AP travel along nerve projections to the
adjacent nucleus tractus solitarius (NTS) and higher regions
of the brain, while those from the HAN do to other parts
of the hypothalamus. Several hormones can cross the blood-
brain barrier, including those with speciﬁc transporters such
as leptin, insulin, and ghrelin [23]. Hormones released from
the gut act on both the enteric nervous system (ENS) to
contribute to the migrating motor complex (MMC) cycle
and the CNS to promote the gradual re-establishment of
appetite. The plasma concentrations of leptin and glucagon-
like peptide 1 (GLP1) are low during fasting, while those of
ghrelin and orexin are high. Signiﬁcant research has focused
on hormones whose plasma concentrations increase during
fasting, as it is hypothesized that these hormones strongly
aﬀecthungerandenergyexpenditure.Inadditiontosystemic
eﬀects, fasting-associated hormones also strongly aﬀect a
myriad of GI functions, possibly preparing the GI tract for
foodreception.Sucharolehasbeenproposedforghrelin,the
ﬁrst orexigenic hormone identiﬁed that is produced in and
released from the stomach. Ghrelin has a well-established
role in increasing appetite and food intake [24, 25] and in
stimulating gastric emptying and acid secretion [26, 27];
these functions are mediated, at least in-part, via vagal nerve
pathways [9, 28]. The details concerning relationship of
ghrelin to the GI tract function and food intake are also
described in several manuscripts of this special issue (see,
e.g., “Ghrelin’s eﬀect on hypothalamic neurons”, “Ghrelin-
NPY axis”, “Gastric ghrelin and leptin”, “Motilin and ghrelin
in the dog,” and “Ghrelin and stress in GI tract”).
4. Plasma Concentrations of Ghrelin in FD
The gut and brain are highly integrated, communicating
bidirectionally through neural and hormonal pathways [29].
Psychosocial factors can signiﬁcantly inﬂuence digestive
function, symptom perception, disease presentation, and
outcome. Functional GI disorders, in return, can alter the
physiologic factors regulating digestion and feeding [22].
The circulating levels of hormones related to appetite
regulation are altered in dyspeptic disorders. Patients with
dysmotility-like dyspepsia have higher serum concentrations
of leptin, which is associated with gastritis and H. pylori
infection [30]. Given that leptin is produced within the
stomach to activate vagal-nerve terminals, reduce appetite,
and increase mucin secretion, leptin may have a protective
role in the upper gut during states of injury [22]. Plasma
ghrelin levels in patients with FD are, however, controversial.
Whilethetotalghrelinlevelswerereportedtobesigniﬁcantly
higher in patients with FD (32 dysmotility-like and 7
ulcer-like FD patients) [31], they were signiﬁcantly lower
in patients with dysmotility-like FD [10, 32]. Concerning
the active ghrelin levels, they were decreased in patients
with postprandial fullness and/or early satiation deﬁned by
the Rome III classiﬁcation [33], whereas similar between
dysmotility-like FD patients and healthy controls [10]. The
reason for discrepancy in plasma ghrelin levels remains
uncertain, warranting further investigation.4 International Journal of Peptides
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Figure 1: Daily food intake was measured before ghrelin injection (days −4t o−2), at the completion of treatment (days 12 to 14), and one
week after injection (days 18 to 20) in ﬁve subjects who completed two weeks of ghrelin treatment. (a) Mean and 95% conﬁdence interval
(CI) for ﬁve subjects; (b) three-day means and SD of daily food intake for each subject.
In terms of pathogenetic implication of these alterations
in plasma ghrelin levels, the relationship with gastric emp-
tying time in these patients was investigated. Signiﬁcant
correlation between the active ghrelin levels and the Tmax
value [33] and delayed gastric empyting in the majority of
patients with abnormally low total ghrelin levels [32]w e r e
observed. In addition, elevations in the acylated form of
ghrelin (active ghrelin) were signiﬁcantly associated with
subjective symptom score in FD patients [12]. Increased
ghrelin concentrations are also seen in patients with duode-
nal and gastric ulcers, suggesting a possible relationship to
mucosal injury [34].
5. GhrelinAdministrationto Patients withFD
The therapies currently available for the treatment of
dyspepsia, and for FD speciﬁcally, target the underlying
hypothesized pathophysiology, including increased gastric
acid sensitivity, delayed gastric emptying, and H. pylori
infection. Only a small proportion of patients, however,
experiences symptomatic relief using these treatments [35].
New treatment modalities targeting impaired gastric accom-
modation, visceral hypersensitivity, and central nervous
system dysfunction are currently under development.
In dysmotility-type FD, which comprises the largest
subset of patients, abnormalities in gastrointestinal motility
and sensitivity are thought to underlie the development
of symptoms. Some patients with FD suﬀer from anorexia
with weight loss, frequently leading to diagnosis with eating
disorders. No treatment guidelines for patients with FD or
eating disorders have been established. As ghrelin increases
gastric emptying [2–6] and promotes feeding [36, 37], we
investigated theability ofrepeatedghrelin administrations to
increase appetite and food intake in patients with FD [38].
We administered ghrelin by intravenous infusion (3μg/kg)
twice a day before breakfast and dinner for two weeks to
ﬁve patients. Ghrelin administration tended to increase daily
food intake by approximately 30% in comparison to levels
before and after completion of treatment, although this
diﬀerence did not reach statistical signiﬁcance (P = .084)
(Figure 1(a)). Increases in food intake were maintained even
one week after treatment (days 18–20). Although the precise
mechanism is not known, the acute eﬀects of ghrelin on
gastric function may lead to sequential improvements in
gastricmucosaand/orfunction.Inaddition,improvementin
food intake may result from decreased anxiety or increased
conﬁdence concerning food intake in these patients. On
an individual basis, food intake increased in four of the
ﬁve subjects tested, decreasing in Patient #5 (Figure 1(b)).
Food intake in Patient #1 was signiﬁcantly elevated at
the end of ghrelin treatment (days 12–14) from levels
observed before treatment (P< .005). Hunger sensation
was signiﬁcantly elevated following a drip infusion (P<
.0001). No severe adverse eﬀects were observed. These results
support the therapeutic potential of ghrelin in patients with
FD. Additional studies, including larger placebo-controlled
trials, will be necessary to conﬁrm the usefulness of ghrelin
in FD treatment.International Journal of Peptides 5
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